FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2158138034> ?p ?o ?g. }

• W2158138034 abstract "Intensified conditioning regimens (increasing the intensity of standard myeloablative conditioning) for hematological malignancies in allogeneic hematopoietic stem cell transplantation (allo-HSCT) could reduce the relapse rate of the underlying disease, but it might simultaneously increase the transplant-related mortality including the mortality of infections. To explore whether intensified conditioning affected Epstein-Barr virus (EBV) and cytomegalovirus (CMV) infections, 185 patients undergoing allo-HSCT were enrolled.A total of 104 cases received standard and 81 intensified conditioning. Cyclosporine A (CsA) withdrawal and/or donor lymphocyte infusion (DLI) were conducted in high-risk patients. The EBV-DNA and CMV-DNA levels of blood were monitored regularly by quantitative real-time polymerase chain reaction (RQ-PCR) and immune reconstitution of recipients were analyzed by flow cytometry.The 3-year cumulative incidence of EBV viremia, EBV-associated diseases and mortality of EBV-associated diseases were 25.3% ± 4.6%, 10.5% ± 3.4% and 0.0% ± 0.0% in the standard group, compared with 45.6% ± 6.5%, 26.0% ±5.3% and 7.3% ± 3.1% in the intensified group (P = 0.002, P = 0.002, P = 0.008). The 3-year cumulative incidence of CMV viremia and CMV-associated diseases, mortality of CMV-associated diseases and incidence of bacterial and fungal infections were similar between the two groups (P = 0.855, P = 0.581, P = 0.933, P = 0.142, P = 0.182, respectively). Multivariate analysis showed that intensified conditioning was one of the risk factors for EBV viremia and EBV-associated diseases (P = 0.037, P = 0.037), but it had no effects on CMV infections. The percentage of CD4+ T cells and CD4+/CD8+ ratio at 3 months post-transplantation were lower in the intensified group (P = 0.032, P = 0.022). The 3-year OS and DFS in the standard group were 62.2% ± 5.8% and 60.6% ± 5.6%, compared with 51.6% ± 6.2% and 51.1% ± 5.9% in the intensified group (P = 0.029, P = 0.063).Intensified conditioning represents a promising approach for high-risk hematological malignancies, although it affects early immune reconstitution of recipients and increases the incidence and mortality of EBV infections." @default.
• W2158138034 created "2016-06-24" @default.
• W2158138034 creator A5000828146 @default.
• W2158138034 creator A5010298865 @default.
• W2158138034 creator A5032457247 @default.
• W2158138034 creator A5041183580 @default.
• W2158138034 creator A5053447705 @default.
• W2158138034 creator A5055145707 @default.
• W2158138034 creator A5071773009 @default.
• W2158138034 creator A5074999356 @default.
• W2158138034 creator A5077083856 @default.
• W2158138034 creator A5081165104 @default.
• W2158138034 date "2012-08-02" @default.
• W2158138034 modified "2023-10-16" @default.
• W2158138034 title "Effects of intensified conditioning on Epstein-Barr virus and cytomegalovirus infections in allogeneic hematopoietic stem cell transplantation for hematological malignancies" @default.
• W2158138034 cites W1540606775 @default.
• W2158138034 cites W1587666812 @default.
• W2158138034 cites W1988530781 @default.
• W2158138034 cites W1988866710 @default.
• W2158138034 cites W1994433299 @default.
• W2158138034 cites W1997129064 @default.
• W2158138034 cites W1997524528 @default.
• W2158138034 cites W1997782298 @default.
• W2158138034 cites W1998458476 @default.
• W2158138034 cites W2012095200 @default.
• W2158138034 cites W2012802827 @default.
• W2158138034 cites W2015483051 @default.
• W2158138034 cites W2023646368 @default.
• W2158138034 cites W2026597916 @default.
• W2158138034 cites W2028568444 @default.
• W2158138034 cites W2054279695 @default.
• W2158138034 cites W2061350936 @default.
• W2158138034 cites W2069716413 @default.
• W2158138034 cites W2073426274 @default.
• W2158138034 cites W2077684036 @default.
• W2158138034 cites W2085600578 @default.
• W2158138034 cites W2086310342 @default.
• W2158138034 cites W2096233660 @default.
• W2158138034 cites W2106947293 @default.
• W2158138034 cites W2125698486 @default.
• W2158138034 cites W2127080762 @default.
• W2158138034 cites W2127630646 @default.
• W2158138034 cites W2131238437 @default.
• W2158138034 cites W2131706663 @default.
• W2158138034 cites W2134117866 @default.
• W2158138034 cites W2134515002 @default.
• W2158138034 cites W2138786761 @default.
• W2158138034 cites W2164143794 @default.
• W2158138034 cites W2165413309 @default.
• W2158138034 cites W4251178308 @default.
• W2158138034 cites W4377470768 @default.
• W2158138034 doi "https://doi.org/10.1186/1756-8722-5-46" @default.
• W2158138034 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3422173" @default.
• W2158138034 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/22856463" @default.
• W2158138034 hasPublicationYear "2012" @default.
• W2158138034 type Work @default.
• W2158138034 sameAs 2158138034 @default.
• W2158138034 citedByCount "60" @default.
• W2158138034 countsByYear W21581380342012 @default.
• W2158138034 countsByYear W21581380342013 @default.
• W2158138034 countsByYear W21581380342014 @default.
• W2158138034 countsByYear W21581380342015 @default.
• W2158138034 countsByYear W21581380342016 @default.
• W2158138034 countsByYear W21581380342017 @default.
• W2158138034 countsByYear W21581380342018 @default.
• W2158138034 countsByYear W21581380342019 @default.
• W2158138034 countsByYear W21581380342020 @default.
• W2158138034 countsByYear W21581380342021 @default.
• W2158138034 countsByYear W21581380342022 @default.
• W2158138034 countsByYear W21581380342023 @default.
• W2158138034 crossrefType "journal-article" @default.
• W2158138034 hasAuthorship W2158138034A5000828146 @default.
• W2158138034 hasAuthorship W2158138034A5010298865 @default.
• W2158138034 hasAuthorship W2158138034A5032457247 @default.
• W2158138034 hasAuthorship W2158138034A5041183580 @default.
• W2158138034 hasAuthorship W2158138034A5053447705 @default.
• W2158138034 hasAuthorship W2158138034A5055145707 @default.
• W2158138034 hasAuthorship W2158138034A5071773009 @default.
• W2158138034 hasAuthorship W2158138034A5074999356 @default.
• W2158138034 hasAuthorship W2158138034A5077083856 @default.
• W2158138034 hasAuthorship W2158138034A5081165104 @default.
• W2158138034 hasBestOaLocation W21581380341 @default.
• W2158138034 hasConcept C120665830 @default.
• W2158138034 hasConcept C121332964 @default.
• W2158138034 hasConcept C126322002 @default.
• W2158138034 hasConcept C194409129 @default.
• W2158138034 hasConcept C203014093 @default.
• W2158138034 hasConcept C2522874641 @default.
• W2158138034 hasConcept C2776185481 @default.
• W2158138034 hasConcept C2776409557 @default.
• W2158138034 hasConcept C2777408962 @default.
• W2158138034 hasConcept C2777732132 @default.
• W2158138034 hasConcept C2780727368 @default.
• W2158138034 hasConcept C2911091166 @default.
• W2158138034 hasConcept C61511704 @default.
• W2158138034 hasConcept C71924100 @default.
• W2158138034 hasConcept C88879693 @default.
• W2158138034 hasConcept C90924648 @default.
• W2158138034 hasConceptScore W2158138034C120665830 @default.
• W2158138034 hasConceptScore W2158138034C121332964 @default.

• next